Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Dusa receives first approval of Levulan PDT for treatment of actinic keratoses

Dec. 10, 1999

Biogen reports phase II data for antipsoriatic agent and advances product to phase III

Dec. 8, 1999

Phase I/II results support the efficacy of ABX-IL-8 in psoriasis

Dec. 2, 1999

Ortec applies for FDA clearance for Composite Cultured Skin

Dec. 2, 1999

Toyama describes quinolones with particularly high potency against P. acnes

Dec. 1, 1999

Clinical trials with IDEC-114 begin following favorable safety and pharmacokinetic results in chimps

Nov. 29, 1999

Topical formulations of ABT-281 in development according to 1999 AAPS presentations

Nov. 29, 1999

Schering AG will handle marketing and sales of Levulan for Dusa; U.S. launch in sight

Nov. 29, 1999

Preliminary phase III results disappointing for Anogesic as anal fissure therapy

Nov. 26, 1999

Launch imminent for Fujisawa's new treatment of atopic dermatitis

Nov. 22, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal
BioWorld
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui...
Unique trial strategy muddies the ODAC waters for camizestrant
BioWorld
Following a discussion that focused more on a new personalized trial strategy rather than the proposed therapy, the U.S. FDA’s Oncologic Drugs Advisory Committee...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...